Nicox to acquire Aciex Therapeutics

Article

Nicox recently announced that it has signed an agreement to acquire all outstanding equity of Aciex Therapeutics, Inc., an ophthalmic development pharmaceutical company based in the United States.

Sophia Antipolis, France-Nicox recently announced that it has signed an agreement to acquire all outstanding equity of Aciex Therapeutics, Inc., an ophthalmic development pharmaceutical company based in the United States. 

Nicox says the acquisition will broaden the company’s therapeutic development pipeline, which will now include

• AC-170 for allergic conjunctivitis, which has completed two phase 3 trials and for which Nicox plans to seek a pre-NDA meeting before the submission of a New Drug Application

• AC-155, in development for post-operative inflammation and pain, which is expected to enter phase 2 studies in 2015

• A collaborative research agreement with Portola Pharmaceuticals, Inc. for small molecule dual Spleen Tyrosine Kinase (Syk)/Janus Kinase (JAK) inhibitors for potential topical ophthalmic treatments

• A portfolio of clinical and pre-clinical product candidates targeting areas such as ocular allergy, dry eye, and other inflammatory eye conditions

• A proprietary manufacturing process that can be used to repurpose existing drugs by producing novel, patentable nanocrystalline forms

According to Nicox, Aciex shareholders will received an upfront payment of $65 million in newly-issued Nicox shares, plus contingent value rights giving right to shares, for a potential additional value of up to $55 million. 

Newsletter

Want more insights like this? Subscribe to Optometry Times and get clinical pearls and practice tips delivered straight to your inbox.

Recent Videos
ODs reflect on their time in Minneapolis, Minnesota, citing continuing education, tech updates, and networking opportunities as valued takeaways from the meeting.
Nora Lee Cothran, OD, FAAO, discussed the importance of optometrists addressing mental health with patients in their chair.
Nora Lee Cothran, OD, FAAO, moderated an Innovation Hub panel that featured 3 companies, giving insights into what's to come in the optometric industry.
Selina McGee, OD, shares what she wants to see in future State of Dry Eye surveys and how this year's results will affect her patient care.
Marc Bloomenstein, OD, FAAO, is a clinical investigator in the trials and overviews the transformative potential of LNZ100.
Shawn Hobbs, OD, previews the annual NOA convention, which takes place in Columbus, Ohio, from July 10 to 12, 2025.
Clark Chang, OD, MSA, MSc, FAAO, gave a presentation alongside Susan Gromacki, OD, MS, FAAO, FSLS, at this year's Optometry's Meeting.
Selina McGee, OD, FAAO, Dipl ABO, shares key takeaways and a personal anecdote relating to the State of Dry Eye survey results.
Devin Sasser, OD, shares his excitement for Acuvue Oasys MAX 1-Day multifocal for astigmatism, the first and only daily disposable multifocal toric contact lens.
Reviewing the State of Dry Eye Survey with Selina McGee, OD, FAAO, Dipl ABO.
© 2025 MJH Life Sciences

All rights reserved.